Dose optimization of contrast-enhanced carotid MR angiography

Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic VALUE study)

BACKGROUND AND PURPOSE

Gadobenate dimeglumine has markedly higher R1 relaxivity compared to gadopentetate dimeglumine meaning that lower doses can be used to achieve similar contrast enhancement. Our aim was to prospectively compare single-dose gadobenate dimeglumine with double-dose gadopentetate dimeglumine for contrast-enhanced MRA of the supra-aortic vasculature.

MATERIALS AND METHODS

Forty-six patients (37 men, 9 women; mean age, 63.5±10.1 years) with known or suspected steno-occlusive disease of the supra-aortic vessels underwent 2 identical CE-MRA examinations at 1.5T. Contrast agents were administered in randomized order, with the 2-fold greater volume of gadopentetate dimeglumine injected at a 2 times faster rate. Image assessment was performed by 3 independent blinded readers for vessel anatomic delineation, detection/exclusion of pathology, and global preference. Diagnostic performance (sensitivity, specificity, accuracy, PPV, and NPV) for detection of ≥60% stenosis was determined for 39/46 patients who underwent preinterventional DSA. Data were analyzed by using the Wilcoxon signed-rank, McNemar, and Wald tests in terms of the noninferiority of single-dose gadobenate dimeglumine compared with double-dose gadopentetate dimeglumine. Quantitative enhancement (signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR)) was also compared.

RESULTS

All images were technically adequate. No differences (P=1.0) were noted by any reader for any qualitative parameter. All readers considered single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine equivalent in at least 42/46 patients (91.3% three-reader agreement) for all parameters. Nonsignificant superiority for gadobenate dimeglumine was reported for all diagnostic performance indicators (sensitivity: 82.7%-88.5% versus 75.0%-80.8%; specificity: 96.4%-98.6% versus 94.6%-98.6%; accuracy: 94.6%-96.1% versus 92.4%-94.9%; PPV: 81.5%-91.5% versus 73.7%-90.7%; NPV: 96.8%-97.8% versus 95.4%-96.4%). No differences (P>.05) in quantitative enhancement were noted.

CONCLUSIONS

The image quality and diagnostic performance achieved with 0.1-mmol/kg gadobenate dimeglumine is at least equivalent to that achieved with 0.2-mmol/kg gadopentetate dimeglumine.

Improved vessel delineation in keyhole time-resolved contrast-enhanced MR angiography using a gadolinium doped flush

PURPOSE

To prospectively assess the influence of a gadolinium doped saline flush compared with a pure saline flush on the image quality of the supra-aortic vessels using time-resolved contrast-enhanced MR angiography (4D CE-MRA) in a randomized double blind clinical trial.

MATERIALS AND METHODS

Twenty-two patients scheduled for contrast-enhanced craniocerebral MRI underwent a supplemental 4D CE-MRA covering the carotids to the superior sinus consisting of 30 dynamics of a T1-weighted 3D gradient-echo sequence (FFE) in sagittal direction. The temporal resolution of 1.1 s per dataset was achieved using the keyhole technique with the reference scan acquired at the end. Immediately after the intravenous (IV) injection of 0.1 mmol Gd/kg body weight of gadoterate, our patients received a 50-mL flush consisting either of a 0.9% saline solution (n = 11) or doped with 50 mM gadolinium (n = 11; total Gd: 0.11 mmol/kg) at a flow-rate of 2 mL/s. Vessel delineation, image quality, signal-to-noise- (SNR) and contrast-to-noise (CNR) ratios over time were compared.

RESULTS

Both vessel delineation (internal carotid artery [ICA]: slope(saline) = 308.5; slope(Gd) = 528.9; P = 0.006; superior sagittal sinus [SSS]: slope(saline) = 505.3; slope(Gd) = 674.9; P = 0.007) and CNR (ICA: CNR(saline) = 57.3; CNR(Gd) = 80.55; P = 0.0417; SSS: CNR(saline) = 74.15; CNR(Gd) = 117.4; P = 0.0331) of the ICA and SSS were significantly increased using the gadolinium doped flush.

CONCLUSION

A low concentrated gadolinium flush in comparison to a pure saline flush improves significantly vessel contrast and their delineation in time-resolved CE-MRA using the keyhole technique.

Supraaortic arteries: contrast material dose reduction at 3.0-T high-spatial-resolution MR angiography--feasibility study

PURPOSE

To evaluate and compare the diagnostic image quality resulting from three contrast agent dose regimens for 3.0-T high-spatial-resolution three-dimensional magnetic resonance (MR) angiography of the supraaortic arteries.

MATERIALS AND METHODS

Institutional review board approval was obtained; informed consent was waived for this HIPAA-compliant study. One hundred twenty consecutive patients who underwent 3.0-T three-dimensional high-spatial-resolution contrast material-enhanced MR angiography of the supraaortic arteries with an identical acquisition protocol were assigned to either the high-dose (0.154 mmol per kilogram of body weight), intermediate-dose (0.097 mmol/kg), or low-dose (0.047 mmol/kg) group. Two readers evaluated resulting images for arterial definition, venous contamination, and arterial stenosis. Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were evaluated at six consistent sites. Statistical analysis was performed with the Kruskal-Wallis, Wilcoxon signed rank, and analysis of variance tests and the kappa coefficient.

RESULTS

Readers 1 and 2 scored vascular definition as excellent or sufficient for diagnosis in 1311 of 1360 segments and in 1313 of 1360 segments in the high-dose group (kappa = 0.73), in 1321 of 1354 and in 1319 of 1354 segments in the intermediate-dose group (kappa = 0.77), and in 1322 of 1350 and in 1320 of 1350 segments in the low-dose group (kappa= 0.66), respectively. Arterial occlusive disease was detected by reader 1 in 52, 27, and 98 segments in the high-, intermediate-, and low-dose groups, respectively. Arterial occlusive disease was detected by reader 2 in 48, 25, and 100 segments in high-, intermediate-, and low-dose groups, respectively. No significant difference existed among the three groups regarding arterial definition scores (reader 1, P = .21; reader 2, P = .25) and venous contamination scores (reader 1, P = .38; reader 2, P = .35). SNRs and CNRs were lower in the low-dose group (P < .01).

CONCLUSION

At 3.0 T, high-spatial-resolution MR angiography of the supraaortic arteries can be performed with contrast agent doses as low as 0.047 mmol/kg, without compromising image quality, acquisition speed, or spatial resolution.

SUPPLEMENTAL MATERIAL

http://radiology.rsnajnls.org/cgi/content/full/249/3/980/DC1http://radiology.rsnajnls.org/cgi/content/full/249/3/980/DC2.

Qualitative and quantitative analysis of routinely postprocessed (CLEAR) CE-MRA data sets: are SNR and CNR calculations reliable?

RATIONALE AND OBJECTIVES

To evaluate objective image quality parameters for contrast-enhanced magnetic resonance angiography (CE-MRA), contrast-to-noise (CNR), and signal-to-noise ratio (SNR) calculations based on signal intensity (SI) and standard deviation (SD) measurements of the vessel, the surrounding tissue (eg, muscle), and the background noise outside the body are commonly used. However, modern magnetic resonance scanners often use dedicated software algorithms such as Constant LEvel AppeaRance (CLEAR) to improve image quality, which may affect the established methods of SNR and CNR calculation. The purpose of this study was to intraindividually evaluate the feasibility of conventional techniques used for SNR and CNR calculation of MRA data sets that have been reconstructed with both, a standard (non-CLEAR) and a CLEAR algorithm.

METHODS

Supra-aortic high-resolution CE-MRA of 11 patients with headache symptoms was performed at 1.5 T using reconstruction algorithms generating both, non-CLEAR and CLEAR-corrected images from the acquired data set. A qualitative analysis with regard to image quality and contrast level was performed by two radiologists applying a score system. For quantitative analysis, distribution of SI values was measured in regions of interest in the common carotid artery (CCA) and the C1 segment of the internal carotid artery in identical positions of both data sets for intraindividual comparison of SNR and CNR calculations. For that purpose, three different equations were used for background noise assessment by determining the SD of SIs measured in the air outside the body (Eq. A), the soft tissue adjacent to the analyzed vessel segment (Eq. B), and in a contrast-medium filled tube (reference standard), which was placed around the patient's neck (Eq. C).

RESULTS

The qualitative analysis documented an improved image quality and a higher contrast level for CLEAR-based data sets. SNR and CNR calculations of the CCA and the C1 segment were significantly different for both reconstruction algorithms when using the background noise outside the body for image noise assessment (P<.05 [CCA]; P<.05 [C1]). SNR and CNR calculations based on the soft tissue adjacent to the analyzed segment or a reference standard were comparable.

CONCLUSIONS

For comparative analysis of CE-MRA data sets, SNR and CNR calculations based on SD determination of the background noise signal measured outside the body are not applicable for CE-MRA data sets reconstructed with a CLEAR-based algorithm. Therefore, noise should rather be assessed in the perivascular tissue to enable proper comparative analysis of CLEAR-enhanced CE-MRA data sets.

Efficacy and safety of gadodiamide (Gd-DTPA-BMA) in renal 3D-magnetic resonance angiography (MRA): a phase II study

PURPOSE

To determine the most efficacious dose of gadodiamide for three-dimensional (3D) contrast-enhanced (CE) magnetic resonance angiography (MRA) of the renal arteries on a patient level based on the sensitivity in detecting the main hemodynamically relevant (> or =50% or occlusion) renal artery stenosis (RAS) using intra-arterial digital subtraction angiography (IA DSA) as the gold standard.

MATERIALS AND METHODS

This prospective, randomized, double-blind, parallel-group, multicenter study included 273 patients referred to IA DSA for suspected RAS. Patients underwent 3D CE MRA after injection of 0.01, 0.05, 0.1, or 0.2mmol/kg of body weight gadodiamide (0.5mmol/ml). The images were assessed for location and degree of RAS by independent blinded readers (MRA: three readers, IA DSA: one reader). Hypothesis testing for a significant trend in sensitivity across dose groups was based on the one-sided Cochran-Armitage style trend test for each independent MRA reader.

RESULTS

The lowest dose group (0.01mmol/kg) proved non-efficacious in detecting hemodynamically relevant (i.e., > or =50% or occlusion) RAS. A statistically significant dose trend (p<0.001) was shown for each of the three independent readers. Depending on reader, the sensitivity obtained with 0.05, 0.1, and 0.2mmol/kg was 63.9-86.1%, 75.8-91.4% and 80.6-90.6%, the specificity was 66.7-73.9%, 59.3-75.0%, and 59.3-75.0% and accuracy was 67.8-78.9%, 75.4-77.4%, and 76.3-81.0%, for the three dose groups, respectively. There were eight non-severe adverse events (AEs). Three serious AEs occurring in one patient were judged not related to gadodiamide by the on-site investigator.

CONCLUSION

A significant dose trend between the four doses examined was observed. The lowest dose (0.01mmol/kg) differed significantly from those of the other three doses. Based on the analysis of the primary and secondary endpoints, 0.1mmol/kg gadodiamide appears to be the most suitable dose in diagnosing hemodynamically relevant RAS. The present study also demonstrated gadodiamide to be safe and well tolerated.